Trials / Conditions / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1

Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1

11 registered clinical trials studyying Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1.

Status	Trial	Sponsor	Phase
Completed	Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01664897	M.D. Anderson Cancer Center	Phase 2
Completed	Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemother NCT01307579	Children's Oncology Group	Phase 3
Completed	Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01238211	National Cancer Institute (NCI)	Phase 2
Completed	Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers NCT01254578	National Cancer Institute (NCI)	Phase 1
Completed	Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacit NCT01168219	National Cancer Institute (NCI)	Phase 2
Completed	Veliparib and Temozolomide in Treating Patients With Acute Leukemia NCT01139970	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leuke NCT00658814	National Cancer Institute (NCI)	Phase 2
Completed	Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leu NCT00588991	National Cancer Institute (NCI)	Phase 1
Completed	Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute NCT00416598	National Cancer Institute (NCI)	Phase 2
Completed	Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission NCT00093470	National Cancer Institute (NCI)	Phase 3
Completed	Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia NCT01005277	Children's Oncology Group	—